Last updated on June 2018

A Study of Otezla in Patients With Plaque Psoriasis Under Routine Conditions

Brief description of study

The objective of this Non-interventional study (NIS) is the collection of data on the utilization of Apremilast under routine conditions in Germany. Patients' quality-of-life and treatment satisfaction on treatment with Apremilast in daily practice will be documented. Moreover, physician's and patient's assessments of the effectiveness and safety of Apremilast will be recorded.

Detailed Study Description

The objective of this NIS (according to section 67(6) of the German Medicinal Products Act) is the documentation of data on the effectiveness and tolerability of an Apremilast treatment under routine clinical conditions in German patients with plaque psoriasis.

This NIS is intended to reflect the apremilast treatment of patients with plaque psoriasis who have received at least one prior conventional, systemic therapy or, if a contraindication is present, did not receive a systemic therapy so far, and who were diagnosed by their treating physicians to be eligible for an apremilast treatment. The treatment of Apremilast will be documented for a period of approximately 52 weeks.

Clinical Study Identifier: NCT02626793

Contact Investigators or Research Sites near you

Start Over

Associate Director Clinical Trial Disclosure

Florian Kreuziger
Vilshofen, Germany